胰腺癌和结直肠癌疫苗：I期AMPLIFY-201试验

IF 51 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-09-08 DOI:10.1038/s41575-025-01123-2

Jordan Hindson

引用次数: 0

摘要

一期AMPLIFY-201临床试验（NCT04853017）的长期随访结果已发表在《自然医学》杂志上。该研究正在调查25名kras突变癌症患者（20名胰腺癌患者和5名结直肠癌患者）在标准局部治疗后使用癌症疫苗ELI-002 2P的情况。ELI-002 2P是一种靶向淋巴结的突变型KRAS （mKRAS）特异性两亲疫苗，先前已证明其安全性和诱导相当大的T细胞反应。更新的结果中位随访时间为19.7个月，没有新的安全信号。ELI-002 2p诱导的mkras特异性T细胞反应的强度与肿瘤生物标志物反应的改善相关。在ELI-002 2P治疗后，67%的患者表现出抗原向疫苗中不存在的个体化肿瘤抗原扩散。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Vaccine for pancreatic and colorectal cancer: phase I AMPLIFY-201 trial

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.